Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers

The expression level of the HER family is unreliable as a predictive marker for targeted therapies in cancer. Thus, there is a need to develop other biomarkers, which can be used to accurately select responsive patients for targeted therapies. The HER dimerization status may be more important than HER receptor expression per se in determining sensitivity or resistance to a given therapeutic agent. The aim of the study is to develop a FRET assay using dye conjugated secondary antibodies to assess HER receptor dimerization. Using primary antibodies from different species in conjunction with Alexa488 and Alexa546 conjugated secondary antibodies, we validated our EGFR/HER2 dimerization assay in three cell lines, EGFR positive A431 cells as well as HER2 positive breast cell lines BT474 and SKBR3 cells. Finally, we applied our assay to assess EGFR/HER2 dimerization in paraffin embedded cell pellets. Our results show promise for the assay to be applied to tumor samples in order to assess the prognostic significance and predictive value of HER receptor dimerization in various cancers.

[1]  T. Jovin,et al.  FRET imaging , 2003, Nature Biotechnology.

[2]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[3]  A. Harris,et al.  HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer , 2010, PLoS biology.

[4]  A. D. Dei Tos,et al.  Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? , 2005, European journal of cancer.

[5]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[6]  J. Swanson,et al.  Fluorescence resonance energy transfer-based stoichiometry in living cells. , 2002, Biophysical journal.

[7]  A. Harris,et al.  Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. , 2006, Cancer research.

[8]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[9]  E. Felip,et al.  Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer , 2011, Oncotarget.

[10]  M. Ozsahin,et al.  The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications , 2006, Radiation oncology.

[11]  G. Fountzilas,et al.  Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study , 2011, Journal of oncology.

[12]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[13]  Peter J. Parker,et al.  HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells , 2008, PloS one.

[14]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Yining Shi,et al.  A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[16]  C. Arteaga.  Epidermal growth factor receptor dependence in human tumors: more than just expression? , 2002, The oncologist.

[17]  M. Kraus,et al.  Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients , 2004, The Journal of pathology.

[18]  D. Wheeler,et al.  Nuclear EGFR contributes to acquired resistance to cetuximab , 2009, Oncogene.

[19]  G. Piontek,et al.  Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck , 2011, Oncotarget.

[20]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[21]  Balazs Halmos,et al.  EGFR-mutated lung cancer: a paradigm of molecular oncology , 2010, Oncotarget.

[22]  Brian Higgins,et al.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.

[23]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[25]  B. Chromy,et al.  Efficient maximum likelihood estimator fitting of histograms , 2010, Nature Methods.

[26]  S. Ameer-Beg,et al.  Multiphoton time-domain fluorescence lifetime imaging microscopy: practical application to protein–protein interactions using global analysis , 2009, Journal of the Royal Society Interface.